ArticleTurk gogus kalp damar cerrahisi dergisi2026
Surgical strategy and outcomes in renal cell carcinoma with inferior vena cava tumor extension: A tertiary center experience.
Article in Turk gogus kalp damar cerrahisi dergisi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Renal cell carcinoma (RCC) may extend into the inferior vena cava (IVC) and, in advanced cases, into the right atrium. Radical nephrectomy with IVC thrombectomy remains the mainstay of treatment; however, the role of cardiopulmonary bypass (CPB) in advanced tumor thrombus remains controversial. This study aimed to evaluate the surgical and early oncologic outcomes of patients with RCC and IVC tumor thrombus and to assess the impact of CPB on perioperative outcomes while cautiously interpreting the findings because of the limited sample size. Methods: We retrospectively analyzed 22 consecutive patients who underwent synchronous radical nephrectomy and IVC thrombectomy between 2009 and 2025 at a tertiary referral center. Patients were divided into two groups: Group I (n=8), who underwent surgery with CPB (± total circulatory arrest), and Group II (n=14), who underwent surgery without CPB. Tumor thrombus level was classified according to the Mayo clinic classification system. Operative variables, perioperative complications, recurrence rates, and survival outcomes were compared. Results: Level II thrombus was the most common presentation, whereas all Level IV cases required CPB. Operative time was significantly longer in the CPB group (267.5±121.4 vs. 190.4±38.7 minutes, p=0.038). Postoperative bleeding was significantly greater in Group I (p=0.001), whereas transfusion requirements, intensive care unit stay, and total hospital stay did not differ significantly between the groups. Perioperative mortality occurred in two patients (25%) in the CPB group and in none in Group II (p=0.16). The overall recurrence rate was 45% and was significantly higher in Group I (p=0.002). The overall 1-year survival rate was 77.2%, with no significant difference between the groups (p=0.12). Conclusion: Radical nephrectomy with IVC thrombectomy may provide acceptable perioperative and early survival outcomes in patients with RCC and venous tumor extension. In this limited series, the use of CPB in patients with advanced tumor thrombus did not appear to significantly increase overall morbidity and may improve operative safety in technically demanding cases. Nevertheless, the interpretation of these findings is limited by the unequal distribution of disease stage between the two groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.